Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
The DOI matches its Crossref record; 16 of the 19 references it cites were found in a registry or an index.
Abstract
The synthetic opioid landscape continues to change as non-fentanyl-related substances appear in forensic toxicology casework. Among the newest synthetic opioids to emerge is isotonitazene, an analogue of a benzimidazole class of analgesic compounds. Isotonitazene is an active and potent synthetic opioid, but the extent to which this compound is causing toxicity among drug users was previously unknown. This report describes the confirmation and quantitation of isotonitazene in blood, urine and vitreous fluid through standard addition, as well as in vivo metabolic profile determination in drug users. Quantitative analysis was performed using liquid chromatography tandem mass spectrometry (LC–MS/MS), and metabolite discovery was performed using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). In total, 18 cases were confirmed positive for isotonitazene, nine of which were previously negative for any opioid. The average isotonitazene concentration in blood was 2.2 ± 2.1 ng/mL (median 1.75 ng/mL, range 0.4–9.5 ng/mL), and the average isotonitazene concentration in urine was 2.4 ± 1.4 ng/mL (median 2.7 ng/mL, range 0.6–4.0 ng/mL). The lowest concentration of isotonitazene in blood was 0.4 ng/mL (two cases) with no other opioids present; findings in death investigations. Four metabolites of isotonitazene were detected in vivo. N- and O-dealkylation products were determined to be the most prominent urinary biomarkers, while 5-amino-isotonitazene was identified in most blood samples. The prevalence and popularity of isotonitazene continue to increase in the United States in early 2020. Toxicologists, medical examiners and coroners should be aware of novel opioids outside the standard scope of testing, especially in medicolegal death investigations. Forensic scientists should add isotonitazene to testing procedures, and public health officials should counsel about potent new drugs and the dangers of opioid use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calello et al. [25] and Amaducci et al. [42,43] reported reversal doses ranging from 0.08 mg to 2.00 mg”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [25]
In the citing paper
“4‐Hydroxy nitazene has previously been hypothesised as a universal metabolite of nitazene analogues [8, 40].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [8]
Citations
Cites
(2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bkt054 · Cited by 873
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
Armenian, P., Vo, K. T., Barr-Walker, J., & Lynch, K. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.016 · Cited by 710 · cited 1×
“After its emergence, illicit fentanyl identifications in seized drug material increased, followed by diversification of the synthetic opioid drug market to include fentanyl analogues (2, 3) and non-fentanylrelated opioids such as U-47700 (4).”
BackgroundA review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016
O’Donnell, J. K., Halpin, J., Mattson, C. L., Goldberger, B. A., & Gladden, R. M. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6643e1 · Cited by 387
Drug Overdose Deaths in the United States, 1999-2015.
Hedegaard, H. B., Warner, M., & Miniño, A. (2017) · PubMed · Cited by 299
A systematic approach to standard addition methods in instrumental analysis
Bader, M. (1980) · Journal of Chemical Education · doi:10.1021/ed057p703 · Cited by 293 · cited 1×
“A workflow by standard addition (4, 18, 19) was developed and validated for quantitative determination of isotonitazene by LC–MSMS.”
MethodMohr, A. L. A., Friscia, M., Papsun, D., Kacinko, S. L., Buzby, D., & Logan, B. K. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw086 · Cited by 199 · cited 4×
“A workflow by standard addition (4, 18, 19) was developed and validated for quantitative determination of isotonitazene by LC–MSMS.”
BackgroundMethodInfluentialSelf-citationThe Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union
Jannetto, P. J., Helander, A., Garg, U., Janis, G. C., Goldberger, B., & Ketha, H. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2017.281626 · Cited by 162
Blanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116
Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161116 · Cited by 103 · cited 1×
“Previously in the literature, several benzimidazole compounds (structural analogues of isotonitazene) were first reported as potential therapeutic agents in the 1950s, including metonitazene, etonitazene and clonitazene (Figure 1) (12, 13).”
Background
Research works printed but not linked: 4
- Drug Enforcement Administration, 2018, Schedules of Controlled Substances: Temporary Placement of Fentanyl-Related Substances in Schedule I
- Hoffmann, 1960, Benzimidazoles, United States Patent Office, 2, 935,514
- Krotulski, 2019, Isotonitazene
- Krotulski, 2019, Potent synthetic opioid—Isotonitazene—Recently identified in the Midwestern United States, NPS Discovery
Cited by
Items 101–155 of 155
Akbaba, M., & Isır, A. B. (2025) · Applied Sciences · doi:10.3390/app15052267 · Cited by 7
Novel Receptor-Binding-Based Assay for the Detection of Opioids in Human Urine Samples
Bergerhoff, M., & Moosmann, B. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03516 · Cited by 5
Tomiyama, K.-I., & Funada, M. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117361 · Cited by 4
Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape
Martins, J. N., dos Santos, B. P., & Arbo, M. D. (2026) · Discover Toxicology · doi:10.1007/s44339-026-00050-4 · Cited by 4
“In the United States, the first fatal case of isotonitazene was reported in August 2019, although it had already been present in the recreational drug market since April of the same year [8]; in addition, the substance has also been identified in Europe and Canada [9–10].”
Truver, M. T., Roman, M., Gomonit, M. M., Gréen, H., Kronstrand, R., & Persson, M. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04407-x · Cited by 4
“Instead, several targeted liquid chromatography–tandem mass spectrometry (LC–MS/MS) assays have been developed to quantitate isotonitazene (Krotulski et al. 2020 ; Mueller et al. 2021; Pardi et al. 2023; Akbaba and Isir 2025), metonitazene (Krotulski et al. 2021), N -pyrrolidino etazene (Vandeputte…”
InfluentialNitazene-related deaths in Norway 2021–2024
Vevelstad, M., Krabseth, H.-M., Haneborg, A.-M., Gundersen, P. O. M., Frost, J., & Øiestad, Å. M. L. (2026) · Forensic Science International · doi:10.1016/j.forsciint.2025.112794 · Cited by 3
Forensic entomotoxicology: Where are we going? 30 years in a review
Beltrame, B., Franceschetti, L., Lodetti, G., Manelli, L., Verzeletti, A., & Bugelli, V. (2026) · Legal Medicine · doi:10.1016/j.legalmed.2026.102843 · Cited by 3
Postmortem findings of organ damage in novel psychoactive substances users: A comprehensive review
Benedetti, B., Conte, C., Bergamin, E., Santo, R. D., Ciasca, G., Corkery, J., Bassi, M., Corli, G., Bilel, S., Schifano, F., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105927 · Cited by 3
Jones, A. W. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad080 · Cited by 3
Toxicology of Specific Substances
Jones, A. W., Mußhoff, F., Kræmer, T., Steuer, A. E., Gerostamoulos, D., Drummer, O. H., Drasch, G. A., Balíková, M., Beyer, J., Teixeira, H. M., et al. (2022) · Wiley eBooks · doi:10.1002/9781119648628.ch52 · Cited by 5
Luba, R. R., & Comer, S. D. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103709 · Cited by 2
Tishion, P., Derrick, D., Sorrentino, J., & Cooper, G. A. A. (2025) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70196 · Cited by 2
Taoussi, O., Carlier, J., Gameli, P. S., Huppertz, L. M., Bambagiotti, G., Tavoletta, F., Tini, A., Berardinelli, D., Busardò, F. P., & Auwärter, V. (2026) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-026-06472-8 · Cited by 2
“Interestingly, and in line with the metabolism of structural analogs, O -deethyl derivatives were predominant in urine, while N -deethyl metabolites were more prevalent in blood [25, 39, 40], which is likely due to a faster urinary elimination of O -dealkyl nitazenes.”
Velez, A., Papsun, D. M., Scott, K. S., & Krotulski, A. J. (2022) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15169 · Cited by 2
“These are commonly seen metabolic transformations in NSOs, such as N- dealkylation seen in the metabolism of isotonitazene [27] and in the metabolism of fentanyl to its major metabolite, norfentanyl [28].”
BackgroundSelf-citationApproach to toxicological deaths
Gilson, T. P., Dolinak, D., Ely, S. F., & Gill, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91796-4.00028-3 · Cited by 3
Lahmy, R., Hübner, H., Gmeiner, P., & König, B. (2024) · ChemPhotoChem · doi:10.1002/cptc.202400022 · Cited by 2
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond Fentanyl
Dow, L. F., Abisogun, A. A., Berida, T. I., Krishnan, S. C., Rathnayake, U., & Lindsley, C. W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00696 · Cited by 3
Al-Juhani, A., Alasmari, A., Aljohani, O. O., Hakeem, H., Desoky, R., Badghaish, M. A., Aljohani, N., & Alanazi, F. A. (2025) · Cureus · doi:10.7759/cureus.99109 · Cited by 1
“Forensic/toxicology evidence-based evaluations similarly demonstrated strong agreement between field LFA testing and mass-spectrometric confirmation when standardized dilution and interpretation procedures were applied [17-20].”
Gofenberg, M. A., Уразаев, Т. Х., & Dvorskaya, O. N. (2024) · Medicina · doi:10.29234/2308-9113-2024-12-2-48-63 · Cited by 1
Analysis of NPS in post-mortem samples in forensic toxicology
Matey, J. M., Menéndez-Quintanal, L. M., Serrano, B. B., González, V. D. F., Zapata, F., Montalvo, G., & García‐Ruiz, C. (2025) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2025.01.006 · Cited by 2
McNicholas, R., Sweeney, N., Fenton, F., & Keenan, E. (2025) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2025.10102 · Cited by 1
“Nitazenes were first identified in Europe in 2019 (Krotulski et al. 2020) and on the island of Ireland in 2022.”
In Vitro Metabolism of a Benzofuran-Substituted Nitazene: Ethyleneoxynitazene
Taoussi, O., Ovat, D. Y., Tavoletta, F., Tini, A., Bambagiotti, G., Carlier, J., Auwärter, V., Busardò, F. P., & Berardinelli, D. (2025) · Metabolites · doi:10.3390/metabo15100679 · Cited by 1
“Nitro reduction has been reported in previous studies as a major biotransformation for several nitazenes, yet its occurrence appears to exhibit significant interindividual variability and the reaction may be underestimated in human hepatocyte incubations [16,18,19].”
Hardwick, E. K., Couch, A. N., & Davidson, J. T. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.70004 · Cited by 1
“…characterization studies have shown, this substitution, as well as the presence of m/z 72.0813 (C 4 H 10 N + ; 0.0 mDa error) and m/z 44.0482 (C 2 H 6 N + ; − 1.8 mDa error), enables the identification of a di-ethyl substitution to the amine group of the core nitazene structure [37, 39, 43, 44].”
InfluentialKashindye, R. C., Yadav, D., & Yadav, R. (2026) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2026.103069 · Cited by 2
Hardwick, E. K., Couch, A. N., & Davidson, J. T. (2026) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.6c00059 · Cited by 1
Lopes‐Paciencia, S., Caron, N. J., Salesse, C., Claveau, J., Laurin, L., & Benkirane, K. (2026) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2026.111131 · Cited by 1
Achieving a more accurate method of standard addition through mathematical improvements
Desharnais, B., Abonamah, J. V., Sofalvi, S., & Mireault, P. (2026) · Journal of Analytical Toxicology · doi:10.1093/jat/bkag047 · Cited by 1
Price of Nitazenes for Sale on Cryptomarkets and Surface Web Shops
Man, N. W. Y., Barratt, M. J., Bruno, R., Graham, C., Sadaphale, V., Peacock, A., & Sutherland, R. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70202 · Cited by 2
“a resurgence in 2019 in illicit drug markets in Europe [2] and North America [6].”
Isotonitazene - A Deadly New Trend in The Psychoactive Substance Abuse
Jangid, C. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5015013 · Cited by 1
Addiction and treatment of novel psychoactive substance dependence
Abdulrahim, D., & Bowden‐Jones, O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818788-3.00005-x · Cited by 1
Modern Psychoactive Substances and Their Detection in Biomedical Samples
Grigoryev, A., & Fateenkov, V. N. (2022) · Journal of NBC Protection Corps · doi:10.35825/10.35825/2587-5728-2022-6-4-320-341 · Cited by 1
Orozco, K. M. L., & Fajardo, F. J. U. (2023) · Ciencia Digital · doi:10.33262/cienciadigital.v7i3.2587 · Cited by 1
Quando os números falam: a evasão da licenciatura em Matemática EaD da Unicesumar de 2014 a 2018
Ramos, A. D. S., & Gomes, P. C. (2020) · Revista de Ensino de Ciências e Matemática · doi:10.26843/rencima.v11i6.2678 · Cited by 2
Jelin, D. F., & Venezuela, A. L. (2022) · Revista de Ensino de Ciências e Matemática · doi:10.26843/rencima.v13n2a01
Nalakath, J., Nelliyott, I. W., Kadry, A. M., Sankar, K. K., & Parseen, O. K. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.10055
Feeney, W. J., Corzo, R., Moorthy, A. S., & Sisco, E. (2025) · Forensic Chemistry · doi:10.1016/j.forc.2025.100705
Development of a Method to Detect Nitazenes in Seized Drug Samples
Bergman, E. N. (2024) · eScholarship (California Digital Library) · Cited by 2
Difficulty in Detecting Opioid-Like Designer Drugs
Protti, M., Mandrioli, R., & Mercolini, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-15015-8_15
Acute toxicity and sex-dependent lethality of isotonitazene in fischer 344 rats
Hernandez, Y. L., Vinerean, H. V., & Aggarwal, S. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1818684
Lepesbayev, M. N., Tarzhanova, D., Mukanova, Z., Mukanov, K., Apbassova, S., Zhakipova, A. A., Уызбаева, И. К., Zhantureyeva, A., & Shabdarbayeva, D. M. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2025.28.1.017
Picht, F., Cepus, V., Hohlfeld, R., Klingbeil, J., & Weber, M. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70074
Opioid-like designer drugs: A practical review of detection, confirmation and interpretation
Protti, M., Iattoni, C. P., Santos, H. M., Lodeiro, C., Capelo, J. L., Lecce, R. D., Mandrioli, R., & Mercolini, L. (2026) · Journal of Pharmaceutical and Biomedical Analysis Open · doi:10.1016/j.jpbao.2026.100112
Dennett, G., & Dennett, B. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6750622
Владимировна, А. А., Pshukova, A. A., Sizhazheva, B. A., Taymaskulova, K. A., Zhanikayev, A. N., Shavaeva, D. I., Ismailov, A. K., Shogenova, M. A., Shogenova, R. A., & Kogotyzheva, E. A. (2026) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn18141
Scully, L., Castle, J. W., Rago, M. D., de Boer, H. H., Schumann, J., Crump, K., Glowacki, L. L., & Gerostamoulos, D. (2026) · Metabolites · doi:10.3390/metabo16060358
“The deaths reported in this series that were attributed to nitazene-related mixed-drug toxicity adds to a concerning trend of nitazene use in Australia and their profound toxicity, particularly in the setting of polydrug use, and even at low concentrations.”
Liu, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9976263/v1
Implementing an accurate method of standard addition using the EZMSA Excel or R tool
Abonamah, J. V., Desharnais, B., Lebrun, É., Sofalvi, S., & Mireault, P. (2026) · Journal of Analytical Toxicology · doi:10.1093/jat/bkag048
Preclinical pharmacology of N-pyrrolidino “nitazene” opioids appearing in nonmedical drug markets
Glatfelter, G. C., Maitland, A. D., Gonzalez, N. R., Walther, D. M., Chen, L., Shi, L., & Baumann, M. H. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104977
Upadhyay, N., Neel, L. T., Li, E., Silte, A. A., Lyu, R., Selley, D. E., Dewey, W. L., Zhang, Y., & Pagare, P. P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00283
Neifeld, J. R., Meli, T. M., & Bartock, S. H. (2026) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70406
Souza, K. A. O., dos Santos, N. C. B. F., Lanaro, R., Walton, S. E., Krotulski, A. J., Logan, B. K., Yonamine, M., & Costa, J. L. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70126 · Cited by 1
“At the same time, protonitazene-related cases may show a wider concentration range, and some severe postmortem cases may exceed the upper limit of the validated interval [2, 14–20].”
Self-citationPortable Electrochemical Screening of Nitazenes: A Proof-of-Concept for On-Site Forensic Detection
Vietti, S. E., Whoriskey, S., Allan, P., & Dennany, L. (2026) · ACS electrochemistry. · doi:10.1021/acselectrochem.6c00210
Kural, K., & Atasoy, S. (2026) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1991289
Zhu, S., Yu, D., Shi, X., Liu, Y., Zong, Y., Wu, N., Wang, N., Tong, G., Liu, Y., Zhang, H., et al. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117762
MacLeod‐Carey, D., & Ulloa, C. O. (2026) · Nanoscale · doi:10.1039/d6nr03226e
Metadata
- Authors
- Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K.
- Affiliations
- Fredric Rieders Family Foundation (US)
- Toxicology Department, NMS Labs, 200 Welsh Rd, Horsham, PA 19044, USA
- Corresponding author
- Krotulski, Alex J
- Venue
- Journal of Analytical Toxicology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-24
- Volume
- 44
- Issue
- 6
- Pages
- 521-530
- ISSN
- 0146-4760 (ISSN-L)
- 1945-2403
- OpenAlex
- W3008681705
- Semantic Scholar
- 448a39d2cd5a8a4e27357b13f5b56754e7582dcf
- Cited by
- 146
- References
- 19
- Citations by year
- 2026: 25 · 2025: 34 · 2024: 21 · 2023: 20 · 2022: 19 · 2021: 15 · 2020: 12
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Analytical Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Historical and Scientific Studies
- Keywords
- isotonitazene, synthetic opioids, opioid metabolites, dealkylation, urinary biomarkers, vitreous fluid, death investigation, drug users, new psychoactive substances
- MeSH terms
- Analgesics, Opioid, Benzimidazoles, Illicit Drugs, Designer Drugs, Substance Abuse Detection, Forensic Toxicology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.